Petrovax Pharm gets the best project of the year award for its market launch of Areima^®

Petrovax Pharm, a Russian biopharmaceutical company, secured a win in the Project of the Year nomination at the 25th Platinum Ounce All-Russian Open Competition of Pharmaceutical Industry Professionals. The experts recognized the Petrovax Pharm’s project to bring the immuno-oncological drug Areima^® (INN: camrelizumab) to market as the best in the Business Project sub-nomination. The award ceremony took place on April 10 in Moscow.

Last year was marked by a breakthrough in the treatment of nasopharyngeal and esophageal cancer as the original innovative drug Areima^® was authorized in Russia. Camrelizumab is a monoclonal antibody that blocks the PD-1 receptor, which reactivates tumor-specific cytotoxic T lymphocytes and stimulates antitumor immunity.

These efforts enabled access for Russian patients with nasopharyngeal cancer, a high mortality type of cancer, to advanced therapeutic methods. Before that, their only option was chemotherapy.

Earlier this year, the Russian Society of Clinical Oncology (RUSSCO) included Areima^® in combination with gemcitabine and cisplatin to its practical guidelines^[1] as the preferred first-line treatment regimen for nasopharyngeal cancer. The Councils of Experts joined by leading Russian oncologists recommended camrelizumab for inclusion in the Clinical Guidelines of the Ministry of Health of the Russian Federation for the Treatment of Esophageal Cancer and Nasopharyngeal Cancer.

The novel therapeutic option makes a substantial contribution to enhancing patient survival and quality of life.